BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 27486174)

  • 1. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
    Lawrence MG; Obinata D; Sandhu S; Selth LA; Wong SQ; Porter LH; Lister N; Pook D; Pezaro CJ; Goode DL; Rebello RJ; Clark AK; Papargiris M; Van Gramberg J; Hanson AR; Banks P; Wang H; Niranjan B; Keerthikumar S; Hedwards S; Huglo A; Yang R; Henzler C; Li Y; Lopez-Campos F; Castro E; Toivanen R; Azad A; Bolton D; Goad J; Grummet J; Harewood L; Kourambas J; Lawrentschuk N; Moon D; Murphy DG; Sengupta S; Snow R; Thorne H; Mitchell C; Pedersen J; Clouston D; Norden S; Ryan A; Dehm SM; Tilley WD; Pearson RB; Hannan RD; Frydenberg M; Furic L; Taylor RA; Risbridger GP
    Eur Urol; 2018 Nov; 74(5):562-572. PubMed ID: 30049486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
    Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
    Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
    Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.
    Cornelison R; Dobbin ZC; Katre AA; Jeong DH; Zhang Y; Chen D; Petrova Y; Llaneza DC; Steg AD; Parsons L; Schneider DA; Landen CN
    Clin Cancer Res; 2017 Nov; 23(21):6529-6540. PubMed ID: 28778862
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
    Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
    Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective targeting of RNA polymerase I in treatment-resistant prostate cancer.
    Low JY; Sirajuddin P; Moubarek M; Agarwal S; Rege A; Guner G; Liu H; Yang Z; De Marzo AM; Bieberich C; Laiho M
    Prostate; 2019 Dec; 79(16):1837-1851. PubMed ID: 31524299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
    Negi SS; Brown P
    Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targeting of RNA Polymerase I With the Small-Molecule CX-5461 for Prevention of Arterial Injury-Induced Neointimal Hyperplasia.
    Ye Q; Pang S; Zhang W; Guo X; Wang J; Zhang Y; Liu Y; Wu X; Jiang F
    Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):476-484. PubMed ID: 28062495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
    Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
    Oncotarget; 2016 Aug; 7(31):49800-49818. PubMed ID: 27391441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
    Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
    Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
    Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
    Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
    Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.